Serum biomarkers in patients with stable and exacerbated COPD‐bronchiectasis overlap syndrome

Sever, Zekiye Kula; Bircan, Hacı Ahmet; Şirin, Fevzıye Burcu; Evrimler, Şehnaz; Çelik, Seda; Merd, Neslihan

doi:10.1111/crj.13238

Cited by 3 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As result of chronic bronchial infection and consequent inflammation in both COPD and bronchiectasis, serum levels of inflammatory biomarkers, such as IL-6, IL-8 and CRP are increased in BCO patients [80]. Also, Nigro et al showed that in BCO patients, the levels of inflammatory cytokines such as IL-2, IL-4, IL-8, IFN-γ, and GM-CSF were significantly higher, while IL-10 expression levels were lower than those of the control group.…”

Section: Copd and Bronchiectasismentioning

confidence: 99%

Comorbidities in COPD: Current and Future Treatment Challenges

Mariniello,

D’Agnano,

Cennamo

et al. 2024

JCM

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition, primarily characterized by the presence of a limited airflow, due to abnormalities of the airways and/or alveoli, that often coexists with other chronic diseases such as lung cancer, cardiovascular diseases, and metabolic disorders. Comorbidities are known to pose a challenge in the assessment and effective management of COPD and are also acknowledged to have an important health and economic burden. Local and systemic inflammation have been proposed as having a potential role in explaining the association between COPD and these comorbidities. Considering that the number of patients with COPD is expected to rise, understanding the mechanisms linking COPD with its comorbidities may help to identify new targets for therapeutic purposes based on multi-dimensional assessments.

show abstract

Section: Copd and Bronchiectasismentioning

confidence: 99%

Comorbidities in COPD: Current and Future Treatment Challenges

Mariniello,

D’Agnano,

Cennamo

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

Comparative Study on Soluble Urokinase-Type Plasminogen Activator Receptor (Supar) and C-Reactive Protein (Crp) Levels in Stable Chronic Obstructive Pulmonary Disease.

Johnson

Das

et al. 2022

Biomed. Pharmacol. J.

View full text Add to dashboard Cite

Background and objective: Chronic obstructive pulmonary disease (COPD) is characterized by a progressive and irreversible airflow limitation. In COPD, the initial low-grade pulmonary inflammation slowly progress to systemic inflammation which is usually confirmed by non-specific inflammatory biomarker like C-reactive protein (CRP). However, the disease progress can be diagnosed at the early stage of pulmonary inflammation by using a novel biomarker, like Soluble urokinase-type plasminogen activator receptor (suPAR) released from the respiratory epithelium in COPD. The objective of this study was to compare the serum levels of suPAR and CRP in stable COPD and to assess the progress of low-grade pulmonary inflammation in COPD. Methods: Stable COPD [SCOPD] study participants (male-35; female-15) and healthy controls (male-38; female-12) were recruited for the study after obtaining informed consent. Based on post-bronchodilator FEV1% predicted values as specified by GOLD criteria, SCOPD study participants were graded into grades I-IV. Serum suPAR and CRP assays were done for all the study participants. Results: The level of suPAR among SCOPD grades I-IV (4.03±0.40 ng/ml; 5.16 ±0.26 ng/ml; 5.82±0.17ng/ml; 6.39±0.07ng/ml respectively) were high compared to healthy control (1.84±0.90ng/ml) and was statistically significant. The level of CRP among SCOPD grade I-IV (3.30±0.13 ng/ml; 3.60 ±0.09 ng/ml; 3.91±0.12ng/ml; 4.41±0.10 ng/ml respectively) were high compared to healthy control (1.63±0.77ng/ml) and was statistically significant.. Conclusion: Our study indicated that serum suPAR and CRP may play an important role in the inflammatory process of COPD particularly in grades III and IV SCOPD. Hence, serum suPAR and CRP measurements may be useful for the evaluation and prognosis of stable COPD.

show abstract

Serum Levels of Urokinase Plasminogen Activator Receptor (suPAR) Discriminate Moderate Uncontrolled from Severe Asthma

Kotsiou

Pantazopoulos

Mavrovounis

et al. 2022

JPM

View full text Add to dashboard Cite

Introduction: The most clinically useful concept in asthma is based on the intensity of treatment required to achieve good asthma control. Biomarkers to guide therapy are needed. Aims: To investigate the role of circulating levels of soluble urokinase plasminogen activator receptor suPAR as a marker for asthma severity. Methods: We recruited patients evaluated at the Asthma Clinic, University of Thessaly, Greece. Asthma severity and control were defined according to the GINA strategy and Asthma Contro Test (ACT). Anthropometrics, spirometry, fractional exhaled nitric oxide (FeNO), suPAR, blood cell count, c-reactive protein (CRP), and analyses of kidney and liver function were obtained. Patients with a history of inflammatory, infectious, or malignant disease or other lung disease, more than 5 pack years of smoking history, or corticosteroid therapy were excluded. Results: We evaluated 74 asthma patients (69% female, mean age 57 ± 17 years, mean body mass index (BMI) 29 ± 6 kg/m2). In total, 24%, 13%, 6%, 5%, 29% and 23% of the participants had mild well-controlled, mild uncontrolled, moderate well-controlled, moderate uncontrolled, severe well-controlled, and severe uncontrolled asthma, respectively. Overall, 67% had T2-high asthma, 26% received biologics (15% and 85% received omalizumab and mepolizumab, respectively), and 34% had persistent airway obstruction. suPAR levels were significantly lower in asthmatics with moderate uncontrolled asthma than in patients with severe uncontrolled asthma without (2.1 ± 0.4 vs. 3.3 ± 0.7 ng/mL, p = 0.023) or with biologics (2.1 ± 0.4 vs. 3.6 ± 0.8 ng/mL, p = 0.029). No correlations were found between suPAR levels and age, BMI, T2 biomarkers, CRP, or spirometric parameters. Conclusions: suPAR levels were higher in asthmatics with severe disease than in those with moderate uncontrolled asthma.

show abstract

Serum biomarkers in patients with stable and exacerbated COPD‐bronchiectasis overlap syndrome

Cited by 3 publications

References 36 publications

Comorbidities in COPD: Current and Future Treatment Challenges

Comorbidities in COPD: Current and Future Treatment Challenges

Comparative Study on Soluble Urokinase-Type Plasminogen Activator Receptor (Supar) and C-Reactive Protein (Crp) Levels in Stable Chronic Obstructive Pulmonary Disease.

Serum Levels of Urokinase Plasminogen Activator Receptor (suPAR) Discriminate Moderate Uncontrolled from Severe Asthma

Contact Info

Product

Resources

About